Trial Profile

Neoadjuvant Olaparib and Durvalumab for Patients With BRCA-associated Triple Negative Breast Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 27 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Olaparib (Primary)
Indications Early breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms NOBLE

Most Recent Events

21 Feb 2024 Planned End Date changed from 18 Feb 2030 to 18 Jul 2030.
21 Feb 2024 Planned primary completion date changed from 6 Sep 2027 to 6 Sep 2028.
21 Feb 2024 Planned initiation date changed from 1 Sep 2022 to 1 Feb 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com